The effect of aripiprazole once-monthly on personal and social functioning: post hoc analyses of acute and long-term studies
Open Access
- 1 June 2019
- journal article
- research article
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 15, 1659-1669
Abstract
Objective: To evaluate the effect of aripiprazole once-monthly 400 mg (AOM 400; Abilify Maintena®,) on personal and social functioning in patients with schizophrenia in both the acute treatment and maintenance therapy settings. Methods: Post hoc analyses were conducted on data from Study 291 (NCT01663532), a 12-week, randomized, double-blind, placebo-controlled trial conducted in patients who were experiencing an acute psychotic episode, and Study 248 (NCT00731549), a 52-week open-label extension of two randomized, controlled trials of AOM 400 as maintenance therapy. Assessment of functioning was made using the Personal and Social Performance (PSP) scale. In Study 291, results were stratified by age (≤35 years or >35 years). Results: In Study 291, 340 patients were included in the analysis (n=168 randomized to AOM 400 [n=49 aged ≤35 years, n=119 aged >35 years]; n=172 randomized to placebo [n=54 aged ≤35 years, n=118 aged >35 years]). In Study 248, 1,081 patients entered the open-label maintenance phase and 858 completed the study. In Study 291, AOM 400, compared with placebo, resulted in a significant increase (improvement) in PSP scores based on LSM (SE) changes from baseline to Week 12 in patients aged ≤35 years (20.6 [1.9] for AOM 400 vs 9.5 [2.4] for placebo; P=0.001) and a numerically (but not significantly) larger increase in PSP scores in patients aged >35 years (16.1 [1.7] for AOM 400 vs 12.5 [1.9] for placebo; P=0.093). Improvements in both age groups met criteria for a minimally important clinical difference (7–10 points). In Study 248, AOM 400 resulted in either numerical improvements (increases) from baseline in PSP total score or maintenance of stable baseline values throughout the study. Conclusion: AOM 400 was effective in improving personal and social functioning during acute treatment and maintaining function during long-term treatment.Keywords
This publication has 41 references indexed in Scilit:
- Humanistic burden in schizophrenia: A literature reviewJournal of Psychiatric Research, 2014
- The social and economic burden of treatment-resistant schizophreniaInternational Clinical Psychopharmacology, 2014
- Examining Levels of Antipsychotic Adherence to Better Understand NonadherenceJournal of Clinical Psychopharmacology, 2013
- Impact of Early Nonadherence to Oral Antipsychotics on Clinical and Economic Outcomes Among Patients with SchizophreniaAdvances in Therapy, 2013
- World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effectsThe World Journal of Biological Psychiatry, 2012
- The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2009Schizophrenia Bulletin, 2009
- The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary StatementsSchizophrenia Bulletin, 2009
- Validation of the Personal and Social Performance (PSP) Scale in a German sample of acutely ill patients with schizophreniaSchizophrenia Research, 2008
- Predicting Medication Noncompliance After Hospital Discharge Among Patients With SchizophreniaPsychiatric Services, 2000
- Factors influencing relapse in the long-term course of schizophreniaSchizophrenia Research, 1997